Pre and post betahistine therapy 99m Tc - HMPAO brain spect studies in patients with vertigo.
Vertebro basilar insufficiency (VBI) is a well known cause of vertigo. Brain Single Photon Emission Computed Tomography (SPECT) is an important diagnostic tool to detect and to quantitate the perfusion abnormalities in different areas of the brain. Effect of an antivertigo drug Betahistine on improving the hypoperfusion in different areas of the brain in vertigo patients was studied using brain SPECT. Betahistine at a dose of 16 mg three times daily was shown to improve perfusion in the hypoperfused areas of the brain resulting in relief from symptoms of vertigo. The cerebellar region, which is the most important area involved in vertigo patients with vascular pathology, showed almost complete normalisation of perfusion following Betahistine therapy.
Krishna
B A
BA
Department of Nuclear Medicine, P.D. Hinduja National Hospital and Medical Research Center, veer savarkar Marg, Mahim, Mumbai, 400016, India.
Kirtane
M V
MV
Sangeeta
T
T
Gopinath
G
G
D001621:Betahistine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014715:Vertebrobasilar Insufficiency / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D014717:Vertigo / Q000000981:diagnostic imaging* / Q000188:drug therapy*
D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D019690:Technetium Tc 99m Exametazime; D001621:Betahistine